Close
Close
Treatment Database
Subcutaneous recombinant human factor IX variant with three point mutations
Trade Name not avaiable
Orphan Indication Treatment for hemophilia B
USA Market Approval
USA Designation Date 20-09-2017
Sponsor Catalyst Biosciences, Inc.
260 Littlefield Avenue
South San Francisco, California, 94080
More about Hemophilia B
Free Newsletter
Related Videos
by Abidemi Uruejoma
10,989 views